Knop

SentinelOne Bolsters Singularity Platform with Executive Appointments

Retrieved on: 
Wednesday, February 22, 2023
Mobile, Wireless, Technology, Security, Telecommunications, Software, Networks, Internet, Hardware, Data Management, Consumer Electronics, UBA, Forrester, Ecosystem, McAfee, Intelligence, Knop, SIEM, NYSE, EDR, Organization, Record, DLP, Gartner, Growth, Culture, Veteran, IDC, Traction, SOAR, Product management, Singularity, SVP, TIP, Splunk, SentinelOne

SentinelOne (NYSE: S), an autonomous cybersecurity platform company, today announced two key executive appointments that will enhance its product and technology leadership team to support the company's continued growth and execution of its Singularity platform.

Key Points: 
  • SentinelOne (NYSE: S), an autonomous cybersecurity platform company, today announced two key executive appointments that will enhance its product and technology leadership team to support the company's continued growth and execution of its Singularity platform.
  • The appointments are a testament to the company's commitment to delivering autonomous cybersecurity built for what's next.
  • "We are pleased to welcome seasoned veterans Jane Wong and Lana Knop to the SentinelOne team," said Tomer Weingarten, CEO, SentinelOne.
  • These capabilities are supported by our platform, which offers unparalleled scale and performance across the petabytes of data we currently ingest daily."

Avicanna Enters Master Supply Agreement with Chilean Pharmaceutical Pioneer Knop Laboratorios S.A.

Retrieved on: 
Friday, January 14, 2022
Aureus, Research, LinkedIn, Perception, MaRS Discovery District, Wellness, Dermatology, Trial of the century, Chronic pain, Knop, National Organ Transplant Act of 1984, Seed, TSX, Lists of diseases, API, Cannabidiol, Risk, Social media, National Organic Program, Bulk, Instagram, Cannabinoid, Company, United States Department of Agriculture, Fair Debt Collection Practices Act, Partnership, SEDAR, FSE, News, RHO, Absorption, Solution, THC, Facebook, GLOBE, GMP, Herbal medicine, Twitter, Prospectus, Fine chemical, Pharmaceutical industry, CBD

TORONTO, Jan. 14, 2022 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company“) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing and commercialization of plant-derived cannabinoid-based products, is pleased to announce that through its majority owned subsidiary Santa Marta Golden Hemp (“SMGH”) the company has entered into a Master Supply Agreement with established Chilean pharmaceutical company Knop Laboratorios S.A. (“Knop”) to supply a range of cannabinoid-based active pharmaceutical ingredients (“API”) for the manufacturing, and commercialization of proprietary cannabinoid-based pharmaceutical products in Latin America.

Key Points: 
  • Knop Laboratorios S.A. is a Chilean pharmaceutical company and pioneer in herbal medicine with more than 90 years of experience in the field and active presence in several Latin American countries including Chile, Ecuador, Colombia, Bolivia, Paraguay, and Peru.
  • With a GMP certified plant located in Quilpu, Chile, Knop Laboratorios serves its markets with high-quality pharmaceutical products.
  • In 2021, Knop opened the first R&D Center in Chile for phytomedicines and active ingredients of natural origin.
  • Knop is carrying out various Clinical Studies for their cannabinoid-based products, with authorization from the appropriate health authorities.